DOCSLIB.ORG

FINE Biological PL 16-17

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FINE Biological PL 16-17 FINE BIOTECH - 2016-17 Catalog Description PackSize Principal Rupees(RS) EU253 5-hydroxytryptamine 96T Fine Biotech 40000 EU381 Folic Acid/Vitamin B9 96T Fine Biotech 40000 EU390 Estradiol 96T Fine Biotech 40000 EU391 Cortisol 96T Fine Biotech 40000 EU392 Dopamine 96T Fine Biotech 40000 EU400 Testosterone 96T Fine Biotech 40000 EU402 Thyroxine 96T Fine Biotech 40000 EU403 Triiodothyronine 96T Fine Biotech 40000 EU2535 Vitamin A 96T Fine Biotech 40000 EU2539 Vitamin B12 96T Fine Biotech 40000 EU2544 25-Hydroxy Vitamin D3 96T Fine Biotech 40000 EU2545 Prostacyclin 96T Fine Biotech 40000 EU2548 8-Hydroxydeoxyguanosine 96T Fine Biotech 40000 EU2549 Oxytocin 96T Fine Biotech 40000 EU2551 Dihydrotestosterone 96T Fine Biotech 40000 EU2554 Prostaglandin E2 96T Fine Biotech 40000 EU2556 Hyaluronic Acid 96T Fine Biotech 40000 EU2558 Free Estriol 96T Fine Biotech 40000 EU2560 3-Nitrotyrosine 96T Fine Biotech 40000 EU2561 8-Epi-Prostaglandin F2 Alpha 96T Fine Biotech 40000 EU2562 Asymmetrical Dimethylarginine 96T Fine Biotech 40000 EU2563 Epinephrine/Adrenaline 96T Fine Biotech 40000 EU2565 Noradrenaline/Norepinephrine 96T Fine Biotech 40000 EU2567 Flavin mononucleotide 96T Fine Biotech 40000 EU2569 Arachidonic Acid 96T Fine Biotech 40000 EU2570 Prostaglandin E1 96T Fine Biotech 40000 EU2571 Lipoxin A4 96T Fine Biotech 40000 EU2572 6-keto-prostaglandin F1a 96T Fine Biotech 40000 EU2573 2,3-dinor Thromboxane B2 96T Fine Biotech 40000 EU2574 Cyclic adenosine monophosphate 96T Fine Biotech 40000 EU2578 Leukotriene B4 96T Fine Biotech 40000 EU2580 Aldosterone 96T Fine Biotech 40000 EU2582 5-Hydroxyindoleacetic Acid 96T Fine Biotech 40000 EH001 CD166 antigen 96T Fine Biotech 40000 EH002 Macrophage Inflammatory Protein 3β 96T Fine Biotech 40000 EH003 Dipeptidyl peptidase 4 96T Fine Biotech 40000 EH004 Clusterin 96T Fine Biotech 40000 EH005 Growth Regulated Oncogene Alpha 96T Fine Biotech 40000 EH006 C-X-C motif chemokine 11 96T Fine Biotech 40000 EH007 Platelet basic protein 96T Fine Biotech 40000 EH008 C-X-C motif chemokine 9 96T Fine Biotech 40000 EH009 Epidermal Growth Factor 96T Fine Biotech 40000 EH010 Epidermal growth factor receptor 96T Fine Biotech 40000 EH011 Interleukin 18 96T Fine Biotech 40000 EH012 Neutrophil Gelatinase Associated Lipocalin 96T Fine Biotech 40000 EH013 Lectin Like Oxidized Low Density Lipoprotein Receptor 1 96T Fine Biotech 40000 1 FINE BIOTECH - 2016-17 Catalog Description PackSize Principal Rupees(RS) EH014 Macrophage Colony-Stimulating Factor 96T Fine Biotech 40000 EH015 MHC class I polypeptide-related sequence A 96T Fine Biotech 40000 EH016 Macrophage migration inhibitory factor 96T Fine Biotech 40000 EH017 Matrix Metalloproteinase 2 96T Fine Biotech 40000 EH018 Myeloperoxidase 96T Fine Biotech 40000 EH020 Cadherin, Placental 96T Fine Biotech 40000 EH021 Platelet/Endothelial Cell Adhesion Molecule 1 96T Fine Biotech 40000 EH022 Placental Growth Factor 96T Fine Biotech 40000 EH023 Thrombospondin-2 96T Fine Biotech 40000 EH024 Vascular Endothelial Growth Factor Receptor 1 96T Fine Biotech 40000 EH025 Alpha-2-macroglobulin 96T Fine Biotech 40000 EH026 Angiotensin I Converting Enzyme 96T Fine Biotech 40000 EH027 Angiotensin-converting enzyme 2 96T Fine Biotech 40000 EH028 Activin A 96T Fine Biotech 40000 EH029 Disintegrin and metalloproteinase domain-containing protein 12 96T Fine Biotech 40000 EH030 Disintegrin and metalloproteinase domain-containing protein 9 96T Fine Biotech 40000 EH031 A disintegrin and metalloproteinase with thrombospondin motifs 1 96T Fine Biotech 40000 EH033 Androgen receptor 96T Fine Biotech 40000 EH034 Angiogenin 96T Fine Biotech 40000 EH035 Angiopoietin-1 96T Fine Biotech 40000 EH036 Angiopoietin-2 96T Fine Biotech 40000 EH038 Angiopoietin-related protein 4 96T Fine Biotech 40000 EH039 Amyloid beta A4 protein 96T Fine Biotech 40000 EH041 Azurocidin 96T Fine Biotech 40000 EH042 B-Cell Activating Factor 96T Fine Biotech 40000 EH043 Brain Derived Neurotrophic Factor 96T Fine Biotech 40000 EH044 Betacellulin 96T Fine Biotech 40000 EH045 Bone Morphogenetic Protein 2 96T Fine Biotech 40000 EH046 Bone Morphogenetic Protein 4 96T Fine Biotech 40000 EH047 Bone Morphogenetic Protein 5 96T Fine Biotech 40000 EH048 Bone Morphogenetic Protein 7 96T Fine Biotech 40000 EH049 Carbonic anhydrase 9 96T Fine Biotech 40000 EH050 Neural Cadherin 96T Fine Biotech 40000 EH051 Cathepsin B 96T Fine Biotech 40000 EH052 Cathepsin D 96T Fine Biotech 40000 EH054 Cathepsin S 96T Fine Biotech 40000 EH056 Monocyte Chemotactic Protein 4 96T Fine Biotech 40000 EH057 Chemokine C-C-Motif Ligand 14 96T Fine Biotech 40000 EH058 C-C motif chemokine 15 96T Fine Biotech 40000 EH059 Chemokine C-C-Motif Ligand 16 96T Fine Biotech 40000 EH060 C-C motif chemokine 17 96T Fine Biotech 40000 EH061 C-C motif chemokine 18 96T Fine Biotech 40000 EH063 C-C motif chemokine 23 96T Fine Biotech 40000 EH064 C-C motif chemokine 24 96T Fine Biotech 40000 EH065 C-C motif chemokine 25 96T Fine Biotech 40000 EH066 C-C motif chemokine 27 96T Fine Biotech 40000 2 FINE BIOTECH - 2016-17 Catalog Description PackSize Principal Rupees(RS) EH067 C-C motif chemokine 4 96T Fine Biotech 40000 EH068 C-C motif chemokine 7 96T Fine Biotech 40000 EH069 C-C motif chemokine 8 96T Fine Biotech 40000 EH070 Neprilysin 96T Fine Biotech 40000 EH071 Endoglin 96T Fine Biotech 40000 EH072 Aminopeptidase N 96T Fine Biotech 40000 EH073 Extracellular Matrix Metalloproteinase Inducer 96T Fine Biotech 40000 EH074 Apolipoprotein B100 96T Fine Biotech 40000 EH075 Soluble Cluster of Differentiation 163 96T Fine Biotech 40000 EH076 Sialic Acid Binding Ig Like Lectin 1 96T Fine Biotech 40000 EH077 OX-2 membrane glycoprotein 96T Fine Biotech 40000 EH078 Complement Receptor 2 96T Fine Biotech 40000 EH079 Receptor II for the Fc Region of Immunoglobulin E 96T Fine Biotech 40000 EH081 Interleukin 2 Receptor Alpha 96T Fine Biotech 40000 EH083 Receptor II for the Fc Fragment of IgG 96T Fine Biotech 40000 EH085 Platelet Membrane Glycoprotein IV 96T Fine Biotech 40000 EH086 Cluster of Differentiation 40 Ligand 96T Fine Biotech 40000 EH087 Neural Cell Adhesion Molecule 96T Fine Biotech 40000 EH088 T-lymphocyte activation antigen CD80 96T Fine Biotech 40000 EH089 Complement component C1q receptor 96T Fine Biotech 40000 EH090 Carcinoembryonic Antigen 96T Fine Biotech 40000 EH091 Complement factor D 96T Fine Biotech 40000 EH092 Chemerin 96T Fine Biotech 40000 EH093 Chitinase-3-like protein 1 96T Fine Biotech 40000 EH094 Hepatocyte growth factor receptor 96T Fine Biotech 40000 EH095 Cartilage oligomeric matrix protein 96T Fine Biotech 40000 EH096 Complement Component 5a 96T Fine Biotech 40000 EH097 Corin 96T Fine Biotech 40000 EH099 C-Reactive Protein 96T Fine Biotech 40000 EH102 Interferon Gamma Induced Protein 10kDa 96T Fine Biotech 40000 EH103 C-X-C motif chemokine 13 96T Fine Biotech 40000 EH104 Transcobalamin-1 96T Fine Biotech 40000 EH105 Chemokine C-X-C-Motif Ligand 16 96T Fine Biotech 40000 EH106 Epithelial Neutrophil Activating Peptide 78 96T Fine Biotech 40000 EH107 C-X-C motif chemokine 6 96T Fine Biotech 40000 EH108 Cysteine Rich Protein, Angiogenic Inducer 61 96T Fine Biotech 40000 EH109 Cystatin B 96T Fine Biotech 40000 EH110 Cystatin C 96T Fine Biotech 40000 EH111 Decorin 96T Fine Biotech 40000 EH113 Dickkopf-related protein 1 96T Fine Biotech 40000 EH114 Dickkopf-related protein 3 96T Fine Biotech 40000 EH115 Delta-like protein 1 96T Fine Biotech 40000 EH116 E-Cadherin 96T Fine Biotech 40000 EH117 Endocrine Gland Derived Vascular Endothelial Growth Factor 96T Fine Biotech 40000 EH118 Peptidase Inhibitor 3, Skin Derived 96T Fine Biotech 40000 EH119 Endostatin 96T Fine Biotech 40000 3 FINE BIOTECH - 2016-17 Catalog Description PackSize Principal Rupees(RS) EH120 Cluster of Differentiation 30 Lligand 96T Fine Biotech 40000 EH121 Eotaxin 96T Fine Biotech 40000 EH122 Endothelial Protein C Receptor 96T Fine Biotech 40000 EH123 Receptor tyrosine-protein kinase erbB-2 96T Fine Biotech 40000 EH124 E-Selectin 96T Fine Biotech 40000 EH125 Endothelial Cell Specific Molecule 1 96T Fine Biotech 40000 EH126 Tumor necrosisfactor receptor superfamily member 6 96T Fine Biotech 40000 EH127 Factor Related Apoptosis Ligand 96T Fine Biotech 40000 EH128 Fetuin A 96T Fine Biotech 40000 EH129 Fibroblast growth factor 19 96T Fine Biotech 40000 EH130 Fibroblast growth factor 21 96T Fine Biotech 40000 EH131 Fibroblast growth factor 4 96T Fine Biotech 40000 EH132 Fibroblast growth factor 7 96T Fine Biotech 40000 EH133 Fibroblast growth factor 9 96T Fine Biotech 40000 EH134 Fibronectin 96T Fine Biotech 40000 EH135 Ficolin-1 96T Fine Biotech 40000 EH136 Ficolin-2 96T Fine Biotech 40000 EH137 Ficolin-3 96T Fine Biotech 40000 EH138 Follistatin-related protein 3 96T Fine Biotech 40000 EH140 Folate receptor alpha 96T Fine Biotech 40000 EH141 Chemokine C-X3-C-Motif Ligand 1 96T Fine Biotech 40000 EH142 Follistatin-related protein 1 96T Fine Biotech 40000 EH143 Furin 96T Fine Biotech 40000 EH144 Galectin-2 96T Fine Biotech 40000 EH145 Galectin-3 96T Fine Biotech 40000 EH146 Galectin-4 96T Fine Biotech 40000 EH147 Galectin-7 96T Fine Biotech 40000 EH148 Galectin-9 96T Fine Biotech 40000 EH149 Granulocyte Colony Stimulating Factor 3 96T Fine Biotech 40000 EH150 Growth Differentiation Factor 15 96T Fine Biotech 40000 EH151 Glial cell line-derived neurotrophic factor 96T Fine Biotech 40000 EH152 Growth Hormone 96T Fine Biotech 40000 EH153 Granulocyte Macrophage Colony Stimulating Factor 96T Fine Biotech 40000 EH154 Interleukin-6 receptor subunit beta 96T Fine Biotech 40000 EH156 Granulysin 96T Fine Biotech 40000
Load more

Recommended publications
  • New York Chapter American College of Physicians Annual
    New York Chapter American College of Physicians Annual Scientific Meeting Poster Presentations Saturday, October 12, 2019 Westchester Hilton Hotel 699 Westchester Avenue Rye Brook, NY New York Chapter American College of Physicians Annual Scientific Meeting Medical Student Clinical Vignette 1 Medical Student Clinical Vignette Adina Amin Medical Student Jessy Epstein, Miguel Lacayo, Emmanuel Morakinyo Touro College of Osteopathic Medicine A Series of Unfortunate Events - A Rare Presentation of Thoracic Outlet Syndrome Venous thoracic outlet syndrome, formerly known as Paget-Schroetter Syndrome, is a condition characterized by spontaneous deep vein thrombosis of the upper extremity. It is a very rare syndrome resulting from anatomical abnormalities of the thoracic outlet, causing thrombosis of the deep veins draining the upper extremity. This disease is also called “effort thrombosis― because of increased association with vigorous and repetitive upper extremity activities. Symptoms include severe upper extremity pain and swelling after strenuous activity. A 31-year-old female with a history of vascular thoracic outlet syndrome, two prior thrombectomies, and right first rib resection presented with symptoms of loss of blood sensation, dull pain in the area, and sharp pain when coughing/sneezing. When the patient had her first blood clot, physical exam was notable for swelling, venous distension, and skin discoloration. The patient had her first thrombectomy in her right upper extremity a couple weeks after the first clot was discovered. Thrombolysis with TPA was initiated, and percutaneous mechanical thrombectomy with angioplasty of the axillary and subclavian veins was performed. Almost immediately after the thrombectomy, the patient had a rethrombosis which was confirmed by ultrasound.
    [Show full text]
  • Differential Expression of Hydroxyurea Transporters in Normal and Polycythemia Vera Hematopoietic Stem and Progenitor Cell Subpopulations
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2021 Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations Tan, Ge ; Meier-Abt, Fabienne Abstract: Polycythemia vera (PV) is a myeloproliferative neoplasm marked by hyperproliferation of the myeloid lineages and the presence of an activating JAK2 mutation. Hydroxyurea (HU) is a standard treat- ment for high-risk patients with PV. Because disease-driving mechanisms are thought to arise in PV stem cells, effective treatments should target primarily the stem cell compartment. We tested for theantipro- liferative effect of patient treatment with HU in fluorescence-activated cell sorting-isolated hematopoietic stem/multipotent progenitor cells (HSC/MPPs) and more committed erythroid progenitors (common myeloid/megakaryocyte-erythrocyte progenitors [CMP/MEPs]) in PV using RNA-sequencing and gene set enrichment analysis. HU treatment led to significant downregulation of gene sets associated with cell proliferation in PV HSCs/MPPs, but not in PV CMP/MEPs. To explore the mechanism underlying this finding, we assessed for expression of solute carrier membrane transporters, which mediate trans- membrane movement of drugs such as HU into target cells. The active HU uptake transporter OCTN1 was upregulated in HSC/MPPs compared with CMP/MEPs of untreated patients with PV, and the HU diffusion facilitator urea transporter B (UTB) was downregulated in HSC/MPPs compared withCM- P/MEPs in all patient and control groups tested. These findings indicate a higher accumulation ofHU within PV HSC/MPPs compared with PV CMP/MEPs and provide an explanation for the differential effects of HU in HSC/MPPs and CMP/MEPs of patients with PV.
    [Show full text]
  • Role of Cornification and Triglyceride Synthesis Genes
    Gillespie et al. BMC Genomics 2013, 14:169 http://www.biomedcentral.com/1471-2164/14/169 RESEARCH ARTICLE Open Access Transcriptome analysis of pigeon milk production – role of cornification and triglyceride synthesis genes Meagan J Gillespie1,2*, Tamsyn M Crowley1,3, Volker R Haring1, Susanne L Wilson1, Jennifer A Harper1, Jean S Payne1, Diane Green1, Paul Monaghan1, John A Donald2, Kevin R Nicholas3 and Robert J Moore1 Abstract Background: The pigeon crop is specially adapted to produce milk that is fed to newly hatched young. The process of pigeon milk production begins when the germinal cell layer of the crop rapidly proliferates in response to prolactin, which results in a mass of epithelial cells that are sloughed from the crop and regurgitated to the young. We proposed that the evolution of pigeon milk built upon the ability of avian keratinocytes to accumulate intracellular neutral lipids during the cornification of the epidermis. However, this cornification process in the pigeon crop has not been characterised. Results: We identified the epidermal differentiation complex in the draft pigeon genome scaffold and found that, like the chicken, it contained beta-keratin genes. These beta-keratin genes can be classified, based on sequence similarity, into several clusters including feather, scale and claw keratins. The cornified cells of the pigeon crop express several cornification-associated genes including cornulin, S100-A9 and A16-like, transglutaminase 6-like and the pigeon ‘lactating’ crop-specific annexin cp35. Beta-keratins play an important role in ‘lactating’ crop, with several claw and scale keratins up-regulated. Additionally, transglutaminase 5 and differential splice variants of transglutaminase 4 are up-regulated along with S100-A10.
    [Show full text]
  • Serum Albumin OS=Homo Sapiens
    Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Computational and Experimental Approaches for Evaluating the Genetic Basis of Mitochondrial Disorders
    Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Lieber, Daniel Solomon. 2013. Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11158264 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders A dissertation presented by Daniel Solomon Lieber to The Committee on Higher Degrees in Systems Biology in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Systems Biology Harvard University Cambridge, Massachusetts April 2013 © 2013 - Daniel Solomon Lieber All rights reserved. Dissertation Adviser: Professor Vamsi K. Mootha Daniel Solomon Lieber Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders Abstract Mitochondria are responsible for some of the cell’s most fundamental biological pathways and metabolic processes, including aerobic ATP production by the mitochondrial respiratory chain. In humans, mitochondrial dysfunction can lead to severe disorders of energy metabolism, which are collectively referred to as mitochondrial disorders and affect approximately 1:5,000 individuals. These disorders are clinically heterogeneous and can affect multiple organ systems, often within a single individual. Symptoms can include myopathy, exercise intolerance, hearing loss, blindness, stroke, seizures, diabetes, and GI dysmotility.
    [Show full text]
  • 1. Ceramide: the Center of Sphingolipid Biosynthesis
    Introduction 1. Ceramide: the center of sphingolipid biosynthesis 1.1. Introducing the sphingolipid family The cell membrane contains three main classes of lipids: glycerolipids, sphingolipids and sterols (Futerman and Hannun 2004; Gulbins and Li 2006; Grassme et al. 2007). First discovered by J.L. W. Thudichum in 1876, sphingolipids were considered to play primarily structural roles in membrane formation (Zheng et al. 2006; Bartke and Hannun 2009). However, by the end of the twentieth century, sphingolipids were described as effector molecules which are involved in the regulation of apoptosis, cell proliferation, cell migration, senescence, and inflammation (Hannun 1996; Perry and Hannun 1998; Hannun and Obeid 2002; Futerman and Hannun 2004; Ogretmen and Hannun 2004; Reynolds et al. 2004; Fox et al. 2006; Modrak et al. 2006; Saddoughi et al. 2008). Sphingolipid metabolism pathways have a unique metabolic entry point, serine palmitoyl transferase (SPT) which forms 3-ketosphinganine, the first sphingolipid in the de novo pathway and a unique exit point, sphingosine-1-phosphate (S1P) lyase, which breaks down S1P into non-sphingolipid molecules. In this network, ceramide can be considered to be a metabolic hub because it occupies a central position in sphingolipid biosynthesis and catabolism (Hannun and Obeid 2008) (Figure 1). 1.2. Ceramide structure and metabolism Ceramide (Cer) from mammalian membranes is composed of sphingosine, which is an amide linked to a fatty acyl chain, varying in length from 14 to 26 carbon atoms (Mimeault 2002; Pettus et al. 2002; Ogretmen and Hannun 2004; Zheng et al. 2006) (Figure 1). Ceramide constitutes the metabolic and structural precursor for complex sphingolipids, which are composed of hydrophilic head groups, such as sphingomyelin, ceramide 1-phosphate, and glucosylceramide (Saddoughi et al.
    [Show full text]
  • Recombinant Human Tissue Transglutaminase for Diagnosis and Follow-Up of Childhood Coeliac Disease
    0031-3998/02/5106-0700 PEDIATRIC RESEARCH Vol. 51, No. 6, 2002 Copyright © 2002 International Pediatric Research Foundation, Inc. Printed in U.S.A. Recombinant Human Tissue Transglutaminase for Diagnosis and Follow-Up of Childhood Coeliac Disease TONY HANSSON, INGRID DAHLBOM, SIV ROGBERG, ANDERS DANNÆUS, PETER HÖPFL, HEIDI GUT, WOLFGANG KRAAZ, AND LARS KLARESKOG Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden [T.H., S.R., L.K.]; Pharmacia Diagnostics, Uppsala, Sweden [I.D.]; Department of Pediatrics [A.D.] and Pathology [W.K.], Uppsala University Hospital, Uppsala, Sweden; and Pharmacia Diagnostics, Freiburg, Germany [P.H., H.G.] ABSTRACT Highly discriminatory markers for celiac disease are needed IgA and IgG anti-tTG. There was already an increase in IgA to identify children with early mucosal lesions and for rapid anti-tTG antibodies after 2 wk of gluten challenge (p Ͻ 0.01). follow-up. The aim of this study was to evaluate the potential of Although the criteria-based diagnosis of childhood celiac disease circulating anti-tissue transglutaminase (tTG) IgA and IgG anti- still depends on histologic evaluation of intestinal biopsies, bodies in the diagnosis and follow-up of childhood celiac dis- detection of anti-tTG antibodies provides useful complementary ease. An ELISA using recombinant human tTG was used to diagnostic information. The human recombinant tTG-based measure the levels of IgA and IgG anti-tTG antibodies in 226 ELISA can be used as a sensitive and specific test to support the serum samples from 57 children with biopsy-verified celiac diagnosis and may also be used in the follow-up of treatment in disease, 29 disease control subjects, and 24 healthy control childhood celiac disease.
    [Show full text]
  • Guinea Pig Transglutaminase Immunolinked Assay Does Not Predict Coeliac Disease in Patients with Chronic Liver Disease
    506 Gut 2001;49:506–511 Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with Gut: first published as 10.1136/gut.49.4.506 on 1 October 2001. Downloaded from chronic liver disease A Carroccio, L Giannitrapani, M Soresi, T Not, G Iacono, C Di Rosa, E Panfili, A Notarbartolo, G Montalto Abstract patients with atrophy of the intestinal Background—It has been suggested that mucosa were positive for anti-tTG while serological screening for coeliac disease all others were negative, including those (CD) should be performed in patients false positive in the ELISA based on with chronic unexplained hypertransami- guinea pig tTG as the antigen. nasaemia. Conclusions—In patients with elevated Aims—To evaluate the specificity for CD transaminases and chronic liver disease diagnosis of serum IgA antitissue trans- there was a high frequency of false glutaminase (tTG) determination in con- positive anti-tTG results using the ELISA secutive patients with chronic based on tTG from guinea pig as the anti- hypertransaminasaemia using the most gen. Indeed, the presence of anti-tTG did widely utilised ELISA based on tTG from not correlate with the presence of EmA or guinea pig as the antigen. CD. These false positives depend on the Patients and methods—We studied 98 presence of hepatic proteins in the com- patients with chronic hypertransamina- mercial tTG obtained from guinea pig saemia, evaluated for the first time in a liver and disappear when human tTG is hepatology clinic. Serum anti-tTG and used as the antigen in the ELISA system. antiendomysial (EmA) assays were per- We suggest that the commonly used tTG formed.
    [Show full text]
  • Exome Sequencing in Gastrointestinal Food Allergies Induced by Multiple Food Proteins
    Exome Sequencing in Gastrointestinal Food Allergies Induced by Multiple Food Proteins Alba Sanchis Juan Department of Biotechnology Universitat Politècnica de València Supervisors: Dr. Javier Chaves Martínez Dr. Ana Bárbara García García Dr. Pablo Marín García This dissertation is submitted for the degree of Doctor of Philosophy September 2019 If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off... no matter what they say. Barbara McClintock Declaration FELIPE JAVIER CHAVES MARTÍNEZ, PhD in Biological Sciences, ANA BÁRBARA GARCÍA GARCÍA, PhD in Pharmacy, and PABLO MARÍN GARCÍA, PhD in Biological Sciences, CERTIFY: That the work “Exome Sequencing in Gastrointestinal Food Allergies Induced by Multiple Food Proteins” has been developed by Alba Sanchis Juan under their supervision in the INCLIVA Biomedical Research Institute, as a Thesis Project in order to obtain the degree of PhD in Biotechnology at the Universitat Politècnica de València. Dr. F. Javier Chaves Martínez Dr. Ana Bárbara García García Dr. Pablo Marín García Acknowledgements Reaching the end of this journey, after so many ups and downs, I cannot but express my gratitude to all those who supported me and helped me through this challenging but rewarding experience. First and foremost, I would like to thank my supervisors, Dr. Javier Chaves Martinez, Dr. Ana Barbara García García and Dr. Pablo Marín García. They gave me the opportunity to work with them when I was still an undergraduate student, and provided me the opportunity to contribute to several exciting projects since then. They also encouraged me into the clinical genomics field and provided me guidance and advice throughout the last four years.
    [Show full text]
  • Daphnia Pulex Lineages in Response to Acute Copper Exposure Sneha Suresh1,2, Teresa J
    Suresh et al. BMC Genomics (2020) 21:433 https://doi.org/10.1186/s12864-020-06831-4 RESEARCH ARTICLE Open Access Alternative splicing is highly variable among Daphnia pulex lineages in response to acute copper exposure Sneha Suresh1,2, Teresa J. Crease3, Melania E. Cristescu4 and Frédéric J. J. Chain1* Abstract Background: Despite being one of the primary mechanisms of gene expression regulation in eukaryotes, alternative splicing is often overlooked in ecotoxicogenomic studies. The process of alternative splicing facilitates the production of multiple mRNA isoforms from a single gene thereby greatly increasing the diversity of the transcriptome and proteome. This process can be important in enabling the organism to cope with stressful conditions. Accurate identification of splice sites using RNA sequencing requires alignment to independent exonic positions within the genome, presenting bioinformatic challenges, particularly when using short read data. Although technological advances allow for the detection of splicing patterns on a genome-wide scale, very little is known about the extent of intraspecies variation in splicing patterns, particularly in response to environmental stressors. In this study, we used RNA-sequencing to study the molecular responses to acute copper exposure in three lineages of Daphnia pulex by focusing on the contribution of alternative splicing in addition to gene expression responses. Results: By comparing the overall gene expression and splicing patterns among all 15 copper-exposed samples and 6 controls, we identified 588 differentially expressed (DE) genes and 16 differentially spliced (DS) genes. Most of the DS genes (13) were not found to be DE, suggesting unique transcriptional regulation in response to copper that went unnoticed with conventional DE analysis.
    [Show full text]
  • Downloaded 18 July 2014 with a 1% False Discovery Rate (FDR)
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer Permalink https://escholarship.org/uc/item/0t47b9ws Author Spiciarich, David Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Professor Matthew B. Francis Professor Amy E. Herr Fall 2017 Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer © 2017 by David Spiciarich Abstract Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich Doctor of Philosophy in Chemistry University of California, Berkeley Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Changes in glycosylation have long been appreciated to be part of the cancer phenotype; sialylated glycans are found at elevated levels on many types of cancer and have been implicated in disease progression. However, the specific glycoproteins that contribute to cell surface sialylation are not well characterized, specifically in bona fide human cancer. Metabolic and bioorthogonal labeling methods have previously enabled enrichment and identification of sialoglycoproteins from cultured cells and model organisms. The goal of this work was to develop technologies that can be used for detecting changes in glycoproteins in clinical models of human cancer.
    [Show full text]